Management of Hyperprolactinemia and Prolactinoma

Diagnosis and Monitoring

Serum prolactin levels should be measured in the morning, in a resting state, to accurately diagnose hyperprolactinemia, which is considered when levels exceed 20 μg/L (or ng/mL), as recommended by the American Academy of Neurology 1
Reference ranges for serum prolactin levels are:
Population Reference Range (ng/mL)
Non-pregnant females 3.0-30.0
Pregnant females 10.0-209.0
Postmenopausal females 2.0-20.0
Regular follow-up of both prolactin levels and tumor size (if applicable) is essential, with cardiac monitoring, including baseline echocardiogram before starting treatment, and yearly echocardiography if dose >2 mg/week, and every 5 years if dose ≤2 mg/week 3

The initial dose of cabergoline for symptomatic hyperprolactinemia or prolactinoma is 0.25 mg twice weekly, with titration by 0.25 mg twice weekly at 4-week intervals, and a maximum dose of typically up to 1 mg twice weekly, as recommended by the American College of Endocrinology 3
Maximum dose for resistant cases can be increased to 3.5 mg/week or up to 7 mg/week in exceptional cases 3
Cabergoline reduces serum prolactin concentrations in 60-70% of patients and induces tumor shrinkage in 80-88% of cases, resolving clinical symptoms including visual defects, menstrual irregularities, and headaches 3
Normalizes prolactin in 83% of patients, demonstrating superior efficacy compared to bromocriptine (59%) 3

If prolactin levels normalize for at least 2 years and no visible tumor is present on MRI, consider gradual dose reduction and monitor prolactin levels for at least 2 more years after discontinuation 3
Patients with normal prolactin levels maintained for ≥6 months can consider dose reduction, with a recommended tapering approach, and discontinuation of cabergoline completely, as recommended by the American College of Endocrinology 3
After discontinuation, prolactin levels should be monitored every 3 months for the first year, and every 6 months for the second year, with monitoring frequency reduced if prolactin levels remain normal for 2 years after discontinuation, as recommended by the American College of Endocrinology 3

Echocardiography surveillance is recommended to monitor for potential cardiac side effects of cabergoline therapy, with an initial echocardiogram at treatment initiation, and yearly echocardiography surveillance for patients receiving >2 mg/week cabergoline and every 5 years if on ≤2 mg/week cabergoline, as recommended by the Endocrine Society 3
The Endocrine Society recommends baseline echocardiogram before starting cabergoline and annual echocardiography if the dose exceeds 2 mg/week, with less frequent monitoring for lower doses 3
For patients on cabergoline with a dose of 2 mg/week or less, echocardiography is recommended every 5 years 3

Patients with visual disturbances should have their vision closely monitored during initial treatment 3
MRI should be performed at intervals to verify tumor shrinkage, with the first assessment at 3 months 3
Large tumors (>20 mm in diameter) may require surgical intervention in addition to medical therapy 3
Resistant cases may require increasing cabergoline dose up to 7 mg/week 3
Cerebrospinal fluid leak can occur due to medication-induced tumor shrinkage, especially in tumors invading the sphenoid bone 3
Younger patients and those with high initial prolactin levels are less likely to achieve complete remission 3
Patients with higher initial prolactin levels, larger initial tumor size, and younger age at diagnosis may require longer treatment before attempting discontinuation, according to the Endocrine Society 3

Side effects of cabergoline occur in about 13% of patients, with common side effects including nausea, dizziness, and headache, and a solution to start with lower doses and titrate slowly, considering nighttime dosing, as recommended by the American College of Endocrinology 3
Indications for surgical referral include resistance to dopamine agonist therapy, intolerance to medical therapy, patient preference for definitive treatment, and deteriorating vision on cabergoline, as recommended by the American Association of Neurological Surgeons 4, 3

For women planning pregnancy, dopamine agonists should be discontinued once pregnancy is confirmed unless there's risk of tumor expansion, with close monitoring during pregnancy recommended by the Endocrine Society and the American College of Obstetricians and Gynecologists 1, 3
The American Urological Association recommends measuring serum prolactin levels in patients with low testosterone levels combined with low or low/normal luteinizing hormone levels to screen for hyperprolactinemia, highlighting the interconnection between prolactin and other hormonal systems 2